A new migraine drug might offer an alternative to people who do not get relief from current medications, a new trial suggests.
The drug, called rimegepant, hasn’t yet been approved by the U.S. Food and Drug Administration. But it belongs to a new class of drugs that has come to the market within the past year — known as CGRP inhibitors.
CGRP is a small protein that is released by the trigeminal nerve during migraine attacks, research shows. It’s believed to play a key role in generating migraine misery.
The three CGRP inhibitors that are already approved by the
